Rubén Darío Flores Saaib Email & Phone Number

Jupiter, Florida, Us

Ligand is a high-growth company with economic rights to several innovative and impactful medicines helping patients around the world live healthier lives.

Regain BioMedicals developed "GRACE", a patented, wearable, novel, non-invasive, personalized, non-neuronal-based device to reduce or eliminate essential tremor. Our device helps patients with essential tremors regain control and increase their quality of life. Regain BioMedicals is also testing the use of its technology platform for the treatment of other involuntary tremors.

San Francisco, California , Us

General Inception was an experimental Venture Studio, comprised of technology developers, exploring new paths to support entrepreneurs before company formation (at inception). During my tenure, I scouted and presented hundreds of opportunities for new company formation, sourced from inventions created at academic centers across the USA and referrals from other investors and entrepreneurs. I also negotiated two license agreements for General Inception startups, structured one major partnership with a corporate partner, and participated in discussions in another. Part of my role at General Inception was to foster collaboration. I worked closely with the operations team to provide a framework to our team for opportunity analysis, tracking, and metrics. This collaborative approach was key to our success in business development.

Los Angeles, Ca, Us

Lead a team of Licensing Associates commercializing inventions in software, the creative arts, social studies, materials, medical devices, telecommunications, entertainment, renewable and alternative energy, biologicals therapeutics and bioengineering.Participate in enhancing the visibility of USC-Stevens across departments on campus and the regional and international innovation community.

La Jolla, Ca, Us

The San Diego Innovation Council (SDIC) convenes the region's premier research-intensive academic centers, along with the organizations that support academic derived inventions. The Council promotes a shared vision for growth through innovation, entrepreneurial activities, and education. Members are committed to supporting commercialization, investment, and new company formation.Through quarterly meetings, and an annual Innovation Showcase in the Fall, the Council aims to reinforce and enhance the economic impact of the greater San Diego region. During the Showcase, the SDIC brings together 30+ technology companies that have a foundation in academic research, along with investors, service providers and entrepreneurs seeking leadership opportunities. Organizations from around the globe attend the annual showcase, including investors from the UK, France, Boston, San Francisco, Asia and Latin America.

La Jolla, Ca, Us

At UC San Diego, my team of 18 licensing managers, marketing, and intellectual property professionals doubled the number of annual startup creation to 32, increased annual licenses 50% to 120 and reduced average time to license completion to six weeks. I championed culture-changing initiatives to focus on customer service, creating productive relationships between UCSD and the business and campus community. I also focused on developing partnerships with entrepreneurs as well as angel, strategic and venture capital investors to support UCSD commercialization activities.From the receipt and management of new invention disclosures to engagement in collaborations across different schools in campus, and the creation of entrepreneurial programs with our local partners, we removed barriers and make campus resources accessible to anyone who wishes to learn how to commercialize a new invention.

Torrance, Ca, Us

Reporting to the CEO, at LA BioMed, I led the group managing the intellectual property portfolio and business relationships. LA BioMed's portfolio included over 200 granted patents in the US and dozens of international patents. My team also managed business relationships with commercial partners funding sponsored research and running over dozens of clinical trials annually at Harbor-UCLA Medical Center.LA BioMed (now The Lundquist Institute) is a non-profit, private research organization located in the Harbor-UCLA Medical Campus in Torrance. Founded in the 1950's, with over 100 active physician researchers and 300,000 sq feet of research space, LA BioMed has been the cradle of innovations such as the modern cholesterol test, surfactants for preemies, Aldurazyme, the nurse practitioner program, the paramedics program and Emmaus Medical, QT Medical and many others.With a strong track record of successful commercialization of clinical technologies in the form of spin-offs, we nurtured this approach, partnering long-term and sharing the potential risk and success with interested parties in the following areas: endocrinology, medical devices, cardiovascular imaging, metabolic disorders, rare genetic diseases, nephrology and pulmonology.

San Diego, Ca, Us

Founded in 1998, GenWay Biotech provides reagents and tools for the Life Sciences market and CLIA laboratory services. At GenWay I managed the strategic planning and operational activities of the custom services business unit, producing specialty reagents and biological assays as OEM services for major diagnostic companies in the US and abroad. In this capacity we expanded the customer base of Genway and secured various contracts to ensure future delivery of specialty reagents. While at Genway we also implemented operational and marketing improvements to the catalog services unit (antibodies, recombinant proteins, ELISA assays and secondary antibodies) resulting in a 20% increase in net sales.

Burlington, Ma, Us

EMD Millipore provides reagents, tools, services and solutions to biopharma, large pharma, basic research and water management organizations. At EMD Millipore my team supported the $1billion annual sales Bioscience Division. I was responsible for retooling the scientific consultant management process to extract real value for new product introduction for EMD Millipore. Our team implemented a world-class process for the presentation, review and timely decision-making of thousands of new opportunities brought to teams across all geographical locations in the Biosciences Division of EMD Millipore.My team was responsible for actively managing key strategic collaborations with a network of 50+ academic scientific consultants and partners for the Bioscience Division of Millipore towards the development of novel reagents, products and services in the areas of Clinical Diagnostics, Biomarkers, Cell Biology, Neurobiology, Stem Cells, Signal Transduction, Post-Translational Modifications, Microfluidics, Protein Separation and High Content Screening.My role as an individual contributor included negotiating business terms, facilitate the execution of licensing agreements and participate in the completion of new product development up until market launch. Our team promoted the recognition of Millipore’s in house R&D capabilities in the scientific community and elevated the profile of Millipore scientists by fostering publications in peer-reviewed journals.Finally, using my expertise in the development, approval and marketing of diagnostic products, I facilitated the workflow between marketing, R&D and regulatory affairs on the design and execution of a business strategies for the regulatory clearance of flow-based diagnostic products for CD4+ monitoring in immunocompromised patients.

Burlington, Ma, Us

As and R&D and Marketing manager, I was responsible for hiring, coaching and mentoring staff and introducing a process for revamping the new product development and regulatory approval efforts of the clinical diagnostics group. In this capacity I managed the groups performing US and world wide clinical operations, research and development and marketing activities for Chemicon's Simulfluor and LightDiagnostics FDA 510(k) and CE regulated diagnostics products. The focus of this group was on the development of diagnostic kits for the detection of respiratory viruses, herpesviruses and enteroviruses in direct and/or cultured patient specimens.During this time I was also responsible for building a group and managing the research and development and manufacturing activities of 14 associates working on over 400 products related to cytokines and cell signaling targets in the Beadlyte product line based on the Luminex platform. One of my first tasks at Serologicals (later EMD Millipore) was to oversee the successful transition of the Luminex Beadlyte portfolio from Lake Placid, NY to Temecula, CA while managing two teams at two different sites. During my tenure in this role I managed the collaborations with academic scientists at Yale and our team developed the FIRST serum-based multiplex biomarker assay for the detection of ovarian cancer.

Abbott Park, Illinois, Us

At Biosite (now Abbott), I was responsible for the design, implementation and management of clinical trials aimed at the discovery of novel plasma biomarkers for sepsis and cardiovascular disease. In this role, I initiated and managed a large, 1000 patient, 10 center, US clinical trial for the identification of plasma serum biomarkers in patients presenting with sepsis at the ED.As a member of the strategic guidance group for new biomarker development in R&D, I investigated, prioritized and recommended the development of specific immuno-assays to novel biomarker targets in plasma. During my tenure at Biosite, I was also responsible for negotiating and executing collaborative agreements for the measurement and discovery of novel biomarkers during drug-based or clinical trials with hospitals and biotechnology companies across the United States.

Franklin Lakes, New Jersey, Us

At BD Biosciences I was responsible for the development of novel immunohistochemical and in situ hibridization reagents for the detection of Th1 and Th2 type cytokines in the Immunopathology group.I managed the work flow for the development of antibody based assays for phospho-specific targets in cell signaling molecules from target selection and antigen design to screening strategies and validation. I also managed the cell culture and ab validation group in the Cell Biology group at BD PharMingen and develop protocols for intracellular staining in flow cytometry applicationsAt BD I was also responsible for collaborative projects in antibody development with academics and other units of BD Biosciences, an experience that provided me with a launchpad towards my focus in business development and clinical trial management.

Ph.D., Biochemistry And Molecular Biology

Bachelor'S Degree, Biology, General